Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma

Ophthalmology. 1996 Feb;103(2):283-8. doi: 10.1016/s0161-6420(96)30703-3.


Purpose: A prospective investigation of the effect of brovincamine fumarate, a Ca2+-channel blocker, on visual field changes in normal-tension glaucoma (NTG).

Methods: A total of 28, age- and field-matched, patients with NTG were allocated randomly to either brovincamine fumarate (20 mg 3 times daily) or placebo (3 times daily). The patients were followed at least every 4 months for a minimum of 2.5 years, and visual field examinations were carried out at least every 6 months. The mean follow-up periods (+/-standard deviation) were 39.1 +/- 8.7 months in the brovincamine-treated group and 37.9 +/- 10.1 months in the placebo group. Stepwise discriminant analyses were performed to separate the patients who showed improvement of their visual fields from those who failed to improve in the brovincamine-treated group, and to identify factors that may determine the visual field prognosis of all patients with NTG enrolled in the study.

Results: In the brovincamine-treated group, six patients showed visual field improvement, whereas none showed improvement in the placebo group using the Statpac 2 linear regression analysis. Discriminant analyses identified better cold recovery rate and higher initial systolic blood pressure to be significantly contributory to a favorable outcome in the brovincamine-treated group, and the use of brovincamine, better cold recovery rate, and higher initial systolic blood pressure were identified to be significantly contributory to a favorable prognosis in all subjects.

Conclusion: Brovincamine seems to have a favorable effect on visual field in at least some patients with NTG.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Calcium Channel Blockers / administration & dosage
  • Calcium Channel Blockers / therapeutic use*
  • Female
  • Follow-Up Studies
  • Glaucoma, Open-Angle / complications*
  • Glaucoma, Open-Angle / physiopathology
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / therapeutic use*
  • Vincamine / administration & dosage
  • Vincamine / analogs & derivatives*
  • Vincamine / therapeutic use
  • Vision Disorders / etiology
  • Vision Disorders / physiopathology
  • Vision Disorders / prevention & control*
  • Visual Acuity
  • Visual Fields / drug effects*


  • Calcium Channel Blockers
  • Vasodilator Agents
  • Vincamine
  • 11-bromovincamine